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Purpose: The purpose of this study was to develop and characterize a novel biolumi-
nescence transgenic mouse model that facilitates rapid evaluation of genetic medicine
delivery methods for inherited and acquired corneal diseases.
Methods: Corneal expression of the firefly luciferase transgene (luc2) was achieved via
insertion into the Krt12 locus, a type I intermediate filament keratin that is exclusively
expressed in the cornea, togenerate theKrt12luc2mouse. The transgene includes amulti-
ple target cassette with human pathogenic mutations in K3 and K12.
Results: The Krt12luc2 mouse exclusively expresses luc2 in the corneal epithelium under
control of the keratin K12 promoter. The luc2 protein is enzymatically active, can be
readily visualized, and exhibits a symmetrically consistent readout. Moreover, structural
integrity of the corneal epithelium is preserved in mice that are heterozygous for the
luc2 transgene (Krt12+/luc2).
Conclusions: This novel Krt12luc2 mouse model represents a potentially ideal in vivo
system for evaluating the efficacies of cornea-targeting gene therapies and for estab-
lishing and/or validating new delivery modalities. Importantly, the multiple targeting
cassette that is included in the Luc2 transgene will greatly reduce mouse numbers
required for in vivo therapy evaluation.
Introduction
Corneal dystrophies represent a heterogeneous
group of heritable diseases in which abnormal endoge-
nous material often accumulates in the cornea. This
can result in loss of transparency, which often leads
to significant vision impairment. Although many
of the causative mutations have been identified,
it is not possible to classify corneal dystrophies
based on the mutated gene/gene product. There-
fore, corneal dystrophies are classified into anatomic
categories: epithelial and subepithelial, epithelial
stromal, stromal, and endothelial. Corneal dystrophies
are mostly inherited as autosomal dominant traits,
with few inherited as autosomal recessive or X-linked
traits.1 The autosomal dominant forms are gener-
ally caused by missense mutations or small in-frame
insertion/deletion mutations in corneal epithelial cell
structural molecules.2,3 Meesmann epithelial corneal
dystrophy (MECD) is a dominant-negative corneal
dystrophy caused by mutations in either of the genes
encoding the corneal specific intermediate filament
proteins keratin 3 (K3) or keratin 12 (K12).4 Mice
expressing a single functional Krt12 allele have no
detectable corneal phenotype, which suggests that
haploinsufficiency is not a concern for K12.5 There-
fore, strategies aimed at transiently or permanently
silencing the mutated disease-causing allele repre-
sent a viable route to therapy for MECD and other
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keratinopathies.6,7 The well-characterized nature of
MECD and the recent development of a humanized
MECD phenotypic mouse model8 together with the
fast intracellular turnover of keratin proteins,7,8 make
this an ideal corneal disease model for the development
of novel genetic therapies, including siRNA.
The cornea is an attractive tissue for gene-based
therapeutics due to its accessibility and small surface
area. Although many methods have been proposed to
deliver genes and/or gene modifying tools to human
cornea, gene therapy for corneal disorders has not yet
entered the clinic. A lack of appropriate animal models
for rapid assessment of therapeutic potency, speci-
ficity, longevity, and disease resolution has certainly
impeded progress in this field. Tissue-specific reporter-
gene animal models allow in vivo assessment of target
tissue bioavailability and efficacy over time using
live animal imaging.9,10 These models greatly reduce
animal numbers required for time course experiments.
We, thus, set out to develop an in vivo reporter corneal
model. Here, we present the generation and character-
ization of a corneal bioluminescence reporter mouse
that would allow researchers to assess the efficacies
of several gene or mutation-specific therapeutics (e.g.
siRNA, antisense oligonucleotides, etc.) in a single
transgenic mouse model, offering further reductions in
transgenic costs and animal use.
Materials and Methods
Multiple Target Cassette
To enable testing of mutation-specific therapeu-
tics against several reported MECD mutations,
a multiple target cassette (MTC) containing the
nucleotides necessary for siRNA targeting for each
of the MECD causing KRT3 and KRT12 mutations:
K3-c.1525G>A (K3-E509K), K3-c.1508G>C (K3-
R503P), K3-c.1493A>T (K3-E498V), K12-c.395T>C
(K12-L132P), and K12-c.404G>C (K12-R135T) was
designed as depicted in Figure 1a. Flanking 5′ NheI
and 3′ XhoI restriction sites were added to enable direc-
tional subcloning. The MTC insert was synthesized
(DNA 2.0 Inc., Menlo Park, CA, USA) and subcloned
into psiTEST-LUC-target vector (York Bioscience
Ltd., York, UK) to enable in vitro validation of
siRNA (see Fig. 1b).
Generation of Krt12luc2 Mice
The MTC construct was inserted into the 3′ UTR
of the luc2 gene in a murine genomic targeting
vector designed for “knock-in” at the Krt12 locus
(Taconic Biosciences, Köln, Germany), as shown
in Figure 1c. Details of the strategy are described in
the Results section. For gene targeting, the vector was
linearized with NotI restriction digestion and trans-
fected by electroporation into the C57BL/6N Tac ES
cell line (Taconic Biosciences). Homologous recombi-
nant ES clones were isolated and validated by PCR
and Southern analysis before injection into blasto-
cysts and re-implantation in pseudopregnant female
mice. Chimeric offspring exhibiting germline trans-
mission were bred. The puromycin resistance cassette
(which could interfere with knock-in allele expres-
sion) was removed by crossing these transgenic mice to
mice universally expressing Flp recombinase. Offspring
were maintained by backcrossing on the C57BL/6
background. Mice were transferred and bred in-house
with WT/heterozygote breeding pairs to achieve age-
matched littermates with WT/heterozygote genotypes.
Requests for this transgenic line should be addressed to
corresponding author Robyn Hickerson, University of
Dundee.
Mouse Genotyping
Animals were used for the following experiments
in accordance with the UK Animal Welfare Act;
the experiments were approved by the Home Office
(Scotland). Genomic DNA (gDNA) was extracted
from ear biopsies by standard protocols (65). Equimo-
lar concentrations of a common reverse primer
(K12KI.R): 5′ TGA ACG GAA CTG TAC TTC
TGT G 3′ and either K12KI.2F: 5′ ACG TCC AGA
CAC AGC ATA GG 3′ or K12KI.1F (5′ GCT GTG
GAG GCC TCT TTT C 3′) were used to detect the
luciferase knock-in allele (299 bp product) and/or the
WT allele (553 bp product), respectively (Fig. 2a). PCR
conditions consisted of an initial denaturation step for
5 minutes at 95°C, 35 cycles of 15 seconds denat-
uration at 95°C, 15 seconds annealing at 60°C, and
30 seconds elongation at 72°C, followed by a final
elongation step of 5 minutes at 72°C usingMyTaq Red
DNA polymerase (Bioline, London, UK).
Live Animal Imaging
All mice used for live imaging were aged between
12 and 25 weeks. For imaging, mice were anesthetized
using 1.5 to 2% isoflurane (Abbott Laboratories
Ltd., Berkshire, UK) in approximately 1.5 L/min flow
of oxygen. A mix of luciferin substrate (30 mg/mL
D-luciferin potassium salt; Gold Biotechnology,
St. Louis, MO, USA) mixed 1:1 w/v with Viscotears
gel (Novartis, Camberley, UK) was dropped onto
the eye of heterozygous Krt12+/luc2 transgenic mice
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Figure 1. Generation and characterization of Krt12luc2 knock-in mouse. (a) The multiple target cassette was designed with short
sequences (∼40 bp each) surrounding the reportedMECD causative mutations in K3 (E509K, R503P, and E498V) and K12 (R135T and L132P)
were synthesized to form the multiple target cassette (MTC). (b) Mouse Krt12 gene (exons in blue) was targeted via homologous recombi-
nation using a vector containing luciferase luc2. Flanking genes are Krt20 (5′) and LOC (3′). The targeting vector contained long and short
homology arms (LHA and SHA, respectively). The construct included amultiple target cassette (MTC)within the 3′ UTR,with polyadenylation
→
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signal hGHpA downstream. An F3-flanked puromycin (PuroR) selection cassette was included within intron 1. Transgene-positive mice were
finally interbred with transgenicmice universally expressing Flp recombinase to remove the PuroR cassette. (c) Dual luciferase in vitro assays
wereperformed to verify thatmRNAs transcribed from theMTCcanbe targetedbymutation specific siRNAs identified for eachmutation. K12
mutation-specific siRNAs were shown to inhibit reporter expression by 75 to 90% at the highest concentration evaluated. An fLUC-specific
siRNA (siLUC) inhibited fLUC expression by 85-90%, whereas a nontargeting siRNA (NSC4) had no effect.
Figure 2. Mouse genotyping strategy. A common reverse primer (5′ TGA ACG GAA CTG TAC TTC TGT G 3′) was used with forward primer
(5′ ACG TCC AGA CAC AGC ATA GG 3′) to detect the luciferase knock-in allele (299 bp product). Alternatively, the forward primer (5′ GCT GTG
GAG GCC TCT TTT C 3′) detected the WT allele (553 bp product). (a) A schematic of WT Krt12 locus and luc2-MTC knock-in allele shows the
positions of genotyping PCR fragments. (b) Exemplar PCRs for the three possible genotypes. PCR reactions containing both bands indicated
heterozygous animals.
immediately prior to imaging. A Xenogen IVIS
Lumina (Perkin Elmer, Cambridge, UK) was
used to quantify luminescence. A region of inter-
est encircling the mouse eye was selected for
quantification whose size and shape was kept
constant throughout, using protocols as previously
described.9
Cell Culture
Human AD293 embryonic kidney cells (Invitrogen,
Paisley, UK) were maintained in Dulbecco’s modified
Eagle’s medium (Invitrogen) with 10% fetal calf serum
(Invitrogen). Cells were incubated at 37°Cwith 5%CO2
supplement and passaged following standard labora-
tory procedures.
Dual Luciferase Reporter Gene Assays
For the validation of MTC functionality
with native siRNA, psiTEST-LUC-MTC (fLUC
reporter) was assessed with siRNAs K12.R135T-
8 (5′ UCUUAAUGAUACAUUAGCU 3′), -9 (5′
CUUAAUGAUACAUUAGCUU 3′), and -13 (5′
AUGAUACAUUAGCUUCCUA 3′) and K12.L132P-
9 (5′ AUGCAAAAUCCUAAUGAUAUU 3′), -14 (5′
AAAUCCUAAUGAUAGAUUAUU 3′), and -15 (5′
AAUCCUAAUGAUAGAUUAGUU 3′) compared
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to control siRNAs (siLUC and NSC4). All siRNAs
were assessed in quadruplicate at 0, 1.25, and 6.25 nM.
To confirm that human allele-specific siRNAs do not
target mK12, siRNAs K12.L132P-9, and K12.R135T-
5 were assessed in conjunction with control siRNAs
against psiTEST-LUC-mK12 (data not shown). All
siRNAs were evaluated in a range from 0 to 6.25 nM
in quadruplicate.
AD293 cells were cells of choice for the luciferase
assay as they do not express endogenous K12.
The Dual-Luciferase Reporter Assay (Promega,
Southampton, UK) was used to measure the effect
of siRNA on luciferase expression according to
manufacturer’s instructions. The general protocol for
assessment of siRNAs by dual luciferase reporter gene
assay was described by Liao and colleagues.11
Histopathology and Immunofluorescence
Eyes were processed for paraffin embedding,
7 μm sections mounted on glass slides and prepared
for staining as previously described.12 Hematoxylin
and eosin staining were performed following standard
protocols. For detection of Luc2p, tissues were blocked
with 10% (v/v) goat serum in PBS for 3 hours prior
to incubation with mouse anti-Luc (L2164; Sigma
USA, Chicago, IL, USA) at 1:20 dilution in blocking
buffer overnight at 4°C. Sections were extensively
washed between antibody incubations with PBS.
Primary antibodies were detected with Alexaflour-594
conjugated anti-mouse and Alexaflour-488 conjugated
anti-rabbit secondary antibodies (Molecular Probes)
at 1:500 dilution in blocking buffer for 30 minutes
at room temperature. All slides for immunofluores-
cence were mounted with Hydromount (National
Diagnostics, Thermo Fisher Scientific, Waltham,
MA, USA) containing 2.5% DABCO (Sigma USA)
and 1 μg/mL DAPI (Roche Diagnostics, Basel,
Switzerland).
Immunoblotting
Whole-tissue protein lysates were prepared from
corneal tissues snap-frozen in liquid nitrogen. Tissues
were ground via mortar and pestle and reconsti-
tuted in 0.5 M Tris, 6.5% SDS, 0.1M DTT, 15%
glycerol, and 0.001% bromophenol blue. Protein
lysates were resolved by SDS-PAGE and processed
for immunoblotting and imaged as described previ-
ously.12,13 Briefly, membranes were simultaneously
probed with a 1:2,000 dilution of rabbit anti-β-actin
(ab8227; Abcam, Cambridge, UK) and a 1:1,000
dilution of mouse anti-Luc (L2164 Sigma-Aldrich,
USA). Membranes were washed, then simultaneously
probed with differentially labeled IR-dye conjugated
secondary antibodies (goat-anti-rabbit 680 and goat-
anti-mouse 800), washed and scanned in the 700 and
800 nm channels using an infrared imaging scanner
(Odyssey Infrared Imaging System; LI-COR Biotech-
nology UK Ltd., Cambridge, UK).
Statistical Analysis
Statistical analysis for the in vivo siRNA exper-
iments was performed using SPSS version 21.
All error bars represent the standard error of the
mean (SEM).
Results
Generation and Characterization of
K12-Luciferase Multitarget Knock-in Mice
To facilitate the assessment of multiple therapeu-
tics that target several, unique genetic mutations using
a single bioluminescent mouse model, we inserted a
synthetic DNA fragment containing several disease-
causing mutations with their flanking sequences into
the 3′ UTR of the mammalian codon optimized firefly
luciferase reporter gene luc2 (see Fig. 1a). Specifically,
this MTC contains a tandem array of the mutation-
specific siRNA target sequences for MECD: K12
(L132P and R135T) and K3 (E509K, R503P, and
E498V).
The validated luc2-MTC construct (see Fig. 1b) was
used to generate K12 knock-in mice (Taconic Artemis,
Köln, Germany) using the targeting strategy and
validated using in vitro luciferase assays (see Fig. 1c).
K12 is exclusively expressed in the anterior corneal
epithelium,14,15 allowing transgene expression to be
directed and restricted to this tissue. A gene-targeting
vector was generated where the coding sequence of
exon 1 of endogenous mouse Krt12 was replaced
with a transgene cassette containing a luc2-MTC gene
fusion and the human growth hormone polyadeny-
lation signal (hGHpA). The positive selection marker
PuroR, flanked by F3 sites, was inserted downstream
of the hGHpA sequence. Mouse genomic sequence
from exon 2 to exon 8 of Krt12 was left intact in order
to preserve all potential regulatory elements driving
expression of Krt12. Homologous recombinant ES
cell clones (C57BL/6NTac ES cell line) were validated
by PCR and Southern analysis and used to generate
mice via blastocyst injection. Founders were crossed
to mice universally expressing flp-recombinase to
excise the PuroR selection cassette. Offspring that were
luc2-positive/PuroR-negative were used for colony
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Figure 3. Characterization of Krt12luc2 knock-in mouse. (a) Bioluminescence imaging of wild-type (Krt12+/+) and heterozygous
(Krt12+/luc2) mice with topical exposure to luciferin injected intraperitoneally with luciferin, shows bioluminescence of the eye/cornea in
heterozygotes. (b) Immunoblotting of corneal protein lysates (n= 3 per genotype) probedwith a luciferase-specific antibody (green) shows
luciferase protein expression in heterozygous animals. β-actin served as a loading control (red). (c) Histology shows that WT and heterozy-
gote corneal epithelium are indistinguishable (hematoxylin and eosin staining). However, the anterior corneal epithelium in homozygotes
(which are K12- null) is thickened, with overt signs of cell fragility, notably cytoplasmic vacuoles (arrows). Immunofluorescence probingwith
an anti-luciferase antibody confirms corneal expression of luc2 in both heterozygous and homozygous animals. E= epithelium, S= stroma.
Scale bar = 100 μm.
establishment. This mouse line was designated
Krt12luc2 and the various genotypes are referred to
as WT = Krt12+/+, heterozygote = Krt12+/luc2, and
homozygote = Krt12luc2/luc2. The genotyping strategy
and example data are shown in Figure 2.
Luciferase transgene expression was confirmed in
the cornea by real-time bioluminescent imaging of
mice that had luciferin substrate applied topically.
Bioluminescent signal was detected in the eye/cornea
of the heterozygous Krt12+/luc2 mice, whereas no
signal was detected in wild-type (WT) animals
(Fig. 3a). Immunoblotting of corneal lysates with a
luciferase-specific antibody confirmed corneal expres-
sion of the reporter gene (n = 3 per genotype; see
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Fig. 3b). Furthermore, immunofluorescence staining
of paraffin-fixed sections showed luciferase protein
expression in the corneal epithelia of both heterozy-
gous and homozygous animals (see Fig. 3c). Histology
showed that the corneal epithelial architecture of
heterozygous animals is indistinguishable to that
of WT mice; however, corneal keratinocytes from
homozygotes exhibit overt morphological changes,
with acanthosis and cytolysis (see Fig. 3c). This is
consistent with the complete loss of K12 expression
(i.e. homozygotes are equivalent to the previously
reported K12-null mice), which exhibit corneal epithe-
lial fragility.5
Optimization of Corneal Bioluminescence
Readout
To ensure reliable therapeutic assessment, daily
live animal bioluminescence measurements should be
quick and consistent over time. Thus, our previously
reported epidermal reporter mouse model luciferin
administration was optimized for corneal biolumi-
nescence read-outs.9 This optimization was required
because we found that intra peritoneal (IP) luciferin
injections were not a suitable route of luciferin deliv-
ery; indeed, eye drop delivery proved more suitable and
provided a more stable and consistent signal.
Luciferin is highly bioavailable and is both rapidly
andwidely distributed.When combinedwith optimiza-
tion of image position for the anesthetized mouse
positioning, highly reproducible bioluminescence
imaging of both eyes was achieved (Fig. 4a). Signal
stability was further enhanced by assessing groups
of animals (see Fig. 4b) and tracking the right-to-left
bioluminescence ratio (R/L ratio). Figure 4c showsR/L
signal stability for a group of 3 mice monitored over
5 consecutive days compared to that of the individual
mice. Thus, a robust in vivo system has been defined
for assessment of corneal gene silencing therapeutics
using right-to-left split body study designs.
Discussion
Several hereditary diseases of the cornea are
transmitted as autosomal dominant traits, and, in
most cases, dominant-negative mutant proteins are
expressed.3,11,16,17 The cornea is particularly well-
suited for gene therapy due to its small size, ease
of visualization, accessibility, and immune privileged
status. These characteristics enable direct delivery
procedures, like topical application or injection, to
readily be used in the clinic.18
Recently, much effort has been expended on devel-
oping genetic therapies, including mutation-specific
siRNA. The siRNA-based therapies hold great thera-
peutic potential for chronic inherited corneal dystro-
phies7 that could be extended to treat acute corneal
conditions. Therapeutic genes have been success-
fully introduced into the cornea using adenoviral
vectors or polyethylenimine-conjugated gold nanopar-
ticles in animal models.19–22 Validation of gene deliv-
ery into the cornea in these studies was performed
by qPCR or immunoblotting. Specific quantifica-
tion of delivery into corneal epithelial cells and
time-dependent analysis in the same animal are
a major challenge with such postmortem whole
tissue techniques. Immunohistochemistry on corneal
explants allows assessment cellular location of trans-
gene expression,23,24 and gene delivery in vivo can
be assessed using a GFP reporter construct in
combination with fluorescence stereomicroscopy.25,26
However, no single technique combines the assess-
ment of corneal sublocalization and gene expression
over time.
The scarcity of methods to specifically deliver thera-
peutic molecules into the appropriate cell populations
of the cornea may slow progression of gene-based
therapies from the laboratory to the clinic. Although
gene therapy for corneal dystrophies is yet to be inves-
tigated in clinical trials (ClinicalTrials.gov, Accessed:
July 2019), there are currently almost 50 interventional
clinical studies underway for gene therapy of retinal
diseases (ClinicalTrials.gov, Accessed: July 2019). A
number of animal models are available for inherited
retinal diseases, as well as in vivo imaging techniques
that allow for long-term noninvasive and repeated
monitoring.27
To address these issues, we have developed a multi-
target corneal reporter gene mouse that supports
real-time in vivo assessment of therapeutic deliv-
ery into the anterior corneal epithelium. Heterozy-
gous Krt12+/luc2 mice show no corneal pathology and
the luciferase reporter gene, knocked into the Krt12
locus, is appropriately and exclusively expressed in the
corneal epithelium (see Fig. 3). The multiple target
cassette within the 3′ UTR of the transgene includes
a range of human pathogenic mutations in K3 and
K12 that we have shown to be targetable with siRNAs
that inhibit mutant allele expression in vitro.11,28,29
This considerably expands the utility of our biolu-
minescent mouse model and reduces the numbers
of transgenic lines required to assess personalized
medicine aimed at specific mutant alleles. This method-
ology should find considerable utility in other genetic
conditions where, like MECD, there is considerable
genetic heterogeneity.
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Figure 4. Optimization of bioluminescent imaging. (a) A bespokemouse holder positioned within the Xenogen IVIS imager at an angle
of 45 degrees enabled both eyes to be simultaneously evaluated in a highly reproduciblemanner. (b) Bioluminescence images from a group
of 3 mice evaluated over 5 consecutive days. (c) Stability of bioluminescent signal from three mice. Signal from the right eye is expressed as
a percentage of the left eye signal (right and left [R/L] ratio %). Signal is more stable when comparing the mean readout of all three mice
(black line), as opposed to individual animals (dashed lines). Error bars represent standard error of the mean.
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In summary, the multitarget bioluminescence
mouse model presented here is an effective tool for
real-time assessment of gene-silencing therapies and
their delivery into the corneal epithelium. TheKrt12luc2
mouse model represents an ideal in vivo system for
iterative testing of a multitude of gene therapy and
delivery system permutations, providing a robust
experimental platform for translation of gene thera-
pies into clinical use.
Acknowledgments
Supported by the United Kingdom Medical
Research Council (MRC) Grants G0801742 and
G0802780 (to W.H.I.M.), Fight for Sight (UK) (to
W.H.I.M.), and Wellcome Trust Strategic Award
098439/Z/12/Z (to W.H.I.M.). R.P.H. was supported
by Marie Curie IIF award 626530 (to W.H.I.M.).
The research was funded by Fight for Sight and
a Wellcome Trust Strategic Award supporting The
Centre for Dermatology and Genetic Medicine. The
sponsor and funding organization had no role in the
design or conduct of this research.
Disclosure: D.J. Fu, None; E.H.A. Allen, None;
R.P. Hickerson, None; D.M. Leslie Pedrioli, None;
W.H.I. McLean, None
* DJF and EHAA contributed equally to this work.
References
1. Lisch W, Weiss JS. Corrigendum to “Clini-
cal and genetic update of corneal dystrophies”
[YEXER 186C (2019) 107715]. Exp Eye Res.
2020;192:107929.
2. Klintworth GK. Corneal dystrophies. Orphanet J
Rare Dis. 2009;4:7.
3. Weiss JS, Møller HU, Aldave AJ, et al. IC3D
Classification of Corneal Dystrophies—Edition 2.
Cornea. 2015;34(2):117–159.
4. Irvine AD, Corden LD, Swensson O, et al. Muta-
tions in cornea-specific keratin K3 or K12 genes
cause Meesmann’s corneal dystrophy. Nat Genet.
1997;16(2):184–187.
5. KaoWW, Liu CY, Converse RL, Shiraishi A, Kao
CW, Ishizaki M, et al. Keratin 12-deficient mice
have fragile corneal epithelia. Invest Ophthalmol
Vis Sci. 1996;37:2572–2584.
6. Omary MB, Bishr Omary M, Coulombe PA,
McLean WHI. Intermediate filament proteins
and their associated diseases. N Engl J Med.
2004;351(20):2087–2100.
7. McLean WHI, Moore CBT. Keratin disor-
ders: from gene to therapy. Hum Mol Genet.
2011;20(R2):R189–R197.
8. Allen EHA, Courtney DG, Atkinson SD, Moore
JE,Mairs L, Poulsen ET, et al. Keratin 12missense
mutation induces the unfolded protein response
and apoptosis in Meesmann epithelial corneal dys-
trophy. HumMol Genet. 2016;25:1176–1191.
9. Hegde V, Hickerson RP, Nainamalai S, et al. In
vivo gene silencing following non-invasive siRNA
delivery into the skin using a novel topical formu-
lation. J Control Release. 2014;196:355–362.
10. Hickerson RP, Smith FJD, Reeves RE, , et al.
Single-nucleotide-specific siRNA targeting in a
dominant-negative skin model. J Invest Dermatol.
2008;128(3):594–605.
11. LiaoH, IrvineAD,MacewenCJ,WeedKH, Porter
L, Corden LD, et al. Development of allele-specific
therapeutic siRNA inMeesmann epithelial corneal
dystrophy. PLoS One. 2011;6:e28582.
12. Fu DJ, Thomson C, Lunny DP, et al. Keratin 9
is required for the structural integrity and termi-
nal differentiation of the palmoplantar epidermis.
J Invest Dermatol. 2014;134(3):754–763.
13. Pedrioli DML, Leslie Pedrioli DM, Fu DJ, et al.
Generic and personalized RNAi-based therapeu-
tics for a dominant-negative epidermal fragility
disorder. J Invest Dermatol. 2012;132(6):1627–
1635.
14. Chaloin-Dufau C, Dhouailly D, Sun T-T. Appear-
ance of the keratin pair K3/K12 during embry-
onic and adult corneal epithelial differentiation
in the chick and in the rabbit. Cell Differ Dev.
1990;32(2):97–108.
15. Liu CY, Zhu G, Westerhausen-Larson A, et al.
Cornea-specific expression of K12 keratin during
mouse development. Curr Eye Res. 1993;12:963–
974.
16. Hassell JR, Birk DE. The molecular basis
of corneal transparency. Exp Eye Res.
2010;91(3):326–335.
17. Biswas S, Munier FL, Yardley J, Hart-Holden
N, Perveen R, Cousin P, et al. Missense muta-
tions in COL8A2, the gene encoding the alpha2
chain of type VIII collagen, cause two forms of
corneal endothelial dystrophy. Hum Mol Genet.
2001;10:2415–2423.
18. Bainbridge JWB, Tan MH, Ali RR. Gene ther-
apy progress and prospects: the eye. Gene Ther.
2006;13(16):1191–1197.
Downloaded from tvst.arvojournals.org on 01/25/2021
A Corneal Bioluminescent Corneal Mouse TVST | December 2020 | Vol. 9 | No. 13 | Article 44 | 10
19. Gupta S, Fink MK, Ghosh A, Tripathi R,
Sinha PR, Sharma A, et al. Novel Combina-
tion BMP7 and HGF Gene Therapy Instigates
Selective Myofibroblast Apoptosis and Reduces
Corneal Haze In Vivo. Invest Ophthalmol Vis Sci.
2018;59:1045–1057.
20. Gupta S, Rodier JT, Sharma A, et al. Targeted
AAV5-Smad7 gene therapy inhibits corneal scar-
ring in vivo. PLoS One. 2017;12(3):e0172928.
21. Mohan RR, Tovey JCK, Sharma A, Schultz
GS, Cowden JW, Tandon A. Targeted decorin
gene therapy delivered with adeno-associated virus
effectively retards corneal neovascularization in
vivo. PLoS One. 2011;6:e26432.
22. Sharma A, Tandon A, Tovey JCK, et al.
Polyethylenimine-conjugated gold nanoparti-
cles: gene transfer potential and low toxicity in the
cornea. Nanomedicine. 2011;7:505–513.
23. Ramo K, Cashman SM, Kumar-Singh R. Evalu-
ation of adenovirus-delivered human CD59 as a
potential therapy for AMD in a model of human
membrane attack complex formation on murine
RPE. Invest Ophthalmol Vis Sci. 2008;49(9):4126–
4136.
24. Kramerov AA, Saghizadeh M, Ljubimov AV.
Adenoviral gene therapy for diabetic keratopathy:
effects on wound healing and stem cell marker
expression in human organ-cultured corneas
and limbal epithelial cells. J Vis Exp. 2016;110:
e54058.
25. Hippert C, Ibanes S, Serratrice N, et al. Corneal
transduction by intra-stromal injection of AAV
vectors in vivo in the mouse and ex vivo in human
explants. PLoS One. 2012;7(4):e35318.
26. Rodier JT, Tripathi R, Fink MK, et al. Linear
polyethylenimine-DNA nanoconstruct for corneal
gene delivery. J Ocul Pharmacol Ther. 2019;35:23–
31.
27. Trapani I, Auricchio A. Seeing the light after 25
years of retinal gene therapy. Trends Mol Med.
2018;24(8):669–681.
28. Allen EHA, Atkinson SD, Liao H, et al. Allele-
specific siRNA silencing for the common ker-
atin 12 founder mutation in Meesmann epithe-
lial corneal dystrophy. Invest Opthalmol Vis Sci.
2013;54(1):494–502.
29. Courtney DG, Atkinson SD, Allen EHA, et al.
siRNA silencing of the mutant keratin 12 allele
in corneal limbal epithelial cells grown from
patients with Meesmann’s epithelial corneal dys-
trophy. Invest Opthalmol Vis Sci. 2014;55(5):3352–
3360.
Downloaded from tvst.arvojournals.org on 01/25/2021
